- Trials with a EudraCT protocol (44,347)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,347 result(s) found.
Displaying page 2,059 of 2,218.
EudraCT Number: 2018-001616-30 | Sponsor Protocol Number: CORT125134-452 | Start Date*: 2018-07-09 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome | |||||||||||||
Medical condition: Endogenous Cushing Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Ongoing) BG (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001217-15 | Sponsor Protocol Number: 85/04/04 | Start Date*: 2004-09-16 |
Sponsor Name:Lassila Riitta | ||
Full Title: PRO-FEIBA. Asetelma on selkeä etenevä satunnaistettu kaksisuuntainen tutkimus aktivoitujen hyytymistekijöiden (aPCC, activated prothrombin complex concentrate) vaikutuksesta vaikeaa A hemofiliaa sa... | ||
Medical condition: A-hemofilia | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-006234-16 | Sponsor Protocol Number: INT003 | Start Date*: 2012-03-27 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refra... | |||||||||||||
Medical condition: Patients bearing neuroendocrine tumour expressing somatostatin receptors refractory to conventional therapies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004535-24 | Sponsor Protocol Number: RLY-4008-101 | Start Date*: 2021-07-07 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Relay Therapeutics, Inc. | ||||||||||||||||||||||||||||||||||||||
Full Title: A First-in-Human Study of Highly Selective FGFR2 inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and other Advanced Solid Tumors | ||||||||||||||||||||||||||||||||||||||
Medical condition: Unresectable or metastatic cholangiocarcinoma (CCA), other advanced solid tumors with an FGFR2-alteration or other potential FGFR2-dependent tumors | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: SE (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005788-34 | Sponsor Protocol Number: NL79578.100.21 | Start Date*: 2022-03-31 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect | ||
Medical condition: Atrial septal defect or patent foramen ovale indicated for percutaneous closure with an occluder device. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002134-14 | Sponsor Protocol Number: 1.0 | Start Date*: 2022-09-02 |
Sponsor Name:Catharina Hospital Eindhoven | ||
Full Title: Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase II study | ||
Medical condition: Patients with peritoneal carcinomatosis of colorectal origin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006367-26 | Sponsor Protocol Number: IGTRegs | Start Date*: 2023-01-03 |
Sponsor Name:Πανεπιστήμιο Πατρών | ||
Full Title: Phase I / II study of HLA-G + induced T-regulatory cells (iG-Tregs) in patients after allogeneic hematopoietic stem cell transplantation from HLA compatible sibling / donor. | ||
Medical condition: Adopt immunotherapy in adult patients undergoing hematopoietic stem cell (HSCT) transplantation from a fully compatible donor sibling for the prevention and treatment of GvHD. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-000245-55 | Sponsor Protocol Number: AGO-GYN 7 | Start Date*: 2008-06-24 |
Sponsor Name:GYN Research GmbH | ||
Full Title: Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors | ||
Medical condition: Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001008-37 | Sponsor Protocol Number: Bab1 | Start Date*: 2005-11-01 |
Sponsor Name:Sahlgrenska University Hospital | ||
Full Title: Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy | ||
Medical condition: Multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022653-41 | Sponsor Protocol Number: INT52/10 | Start Date*: 2010-11-25 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder. | |||||||||||||
Medical condition: Muscle-invasive transitional cell carcinoma of the bladder at clinical stage T>/=2N0. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002330-23 | Sponsor Protocol Number: 9794 | Start Date*: 2017-11-24 | |||||||||||
Sponsor Name:University hospital of Montpellier | |||||||||||||
Full Title: HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA: A MULTICENTRIC SINGLE-ARM PHASE II STUDY | |||||||||||||
Medical condition: The combination of gemcitabine and oxaliplatin intra-arterial as second-line therapy can greatly improve the Objective Response Disorder (ORT) at 4 months | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005248-81 | Sponsor Protocol Number: INT0111 | Start Date*: 2012-01-31 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: Differentiated thyroid cancer: metabolic radiotherapy with high activity of radioiodine calculated by individual pre-therapy dosimetry | |||||||||||||
Medical condition: Patients bearing differentiated thyroid carcinoma with distant metastases, candidated to metabolic radiotherapy after surgery or repetition of same therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002096-14 | Sponsor Protocol Number: MF115 | Start Date*: 2015-08-28 |
Sponsor Name:Sahlgrenska University Hospital | ||
Full Title: Examine whether treatment with methylphenidate facilitates work rehabilitation for persons with long-term pain and mental fatigue after traumatic brain injury. | ||
Medical condition: Long-term pain and mental fatigue after traumatic brain injury and work rehabilitation. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004653-24 | Sponsor Protocol Number: ARBAS041218 | Start Date*: 2020-06-15 | |||||||||||
Sponsor Name:Odense Universitets Hospital | |||||||||||||
Full Title: Impact of an Angiotensin Receptor Blocker in Aortic Stenosis – A Randomized Controlled Trial | |||||||||||||
Medical condition: Aortic valve stenosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003529-13 | Sponsor Protocol Number: 010617 | Start Date*: 2017-10-19 | |||||||||||
Sponsor Name:Thomas Benfield | |||||||||||||
Full Title: Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacterermia: A randomized, non-blinded, non-inferiority interventional study | |||||||||||||
Medical condition: Staphylococcus aureus bacteremia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004361-40 | Sponsor Protocol Number: 2013/CHU/12 | Start Date*: 2020-12-18 | |||||||||||
Sponsor Name:CHU de la Réunion | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001145-40 | Sponsor Protocol Number: P17-03 | Start Date*: 2019-11-06 | ||||||||||||||||
Sponsor Name:Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts | ||||||||||||||||||
Full Title: French prospective open label phase II randomized non-comparative study of SC tocilizumab associated with IV pulse steroid versus IV pulse steroid alone for the treatment of acute anterior ischemic... | ||||||||||||||||||
Medical condition: Giant cell arteritis, acute anterior ischemic optic neuropathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001300-22 | Sponsor Protocol Number: PHRCI/2013/MV-001 | Start Date*: 2014-12-17 | |||||||||||
Sponsor Name:CHU de Nîmes | |||||||||||||
Full Title: Evaluation de trois types d’infiltrations dans le cadre du traitement des épicondylalgies latérales : Leukocyte – Platelet Rich Plasma (L-PRP) versus Toxine botulique de type A (Xeomin®, MERZ) vers... | |||||||||||||
Medical condition: epicondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021898-36 | Sponsor Protocol Number: INT 38/10 | Start Date*: 2010-10-20 | ||||||||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | ||||||||||||||||||
Full Title: Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment. | ||||||||||||||||||
Medical condition: Patients with metastatic germ-cell tumors failing first-line treatment. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020375-24 | Sponsor Protocol Number: 2010 - 020375 - 24 | Start Date*: 2010-08-11 | ||||||||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | ||||||||||||||||||
Full Title: Sorafenib in recurrent and/or metastatic salivary gland carcinomas | ||||||||||||||||||
Medical condition: advanced/metastatic disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
